Macimorelin as a Diagnostic Test for Adult GH Deficiency

What Was Tested

Researchers studied Macimorelin (non-peptide) in this randomized controlled trial publication.

The diagnosis of adult GH deficiency (AGHD) is challenging and often requires confirmation with a GH stimulation test (GHST).

The insulin tolerance test (ITT) is considered the reference standard GHST but is labor intensive, can cause severe hypoglycemia, and is contraindicated for certain patients.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label, crossover and multicenter study.

Because people in this Macimorelin (non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Macimorelin (non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Macimorelin (non-peptide) and the comparison at some point, usually with a gap in between.

Running at several centres spread the Macimorelin (non-peptide) study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Age of Onset, Diagnostic Tests, Routine, Human Growth Hormone, Hypopituitarism, Indoles, Pituitary Function Tests and Reproducibility of Results.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Macimorelin (non-peptide).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Macimorelin (non-peptide) compound page, all human trials.